key: cord-0989816-klnkw3tn
authors: Thee, Stephanie; Busack, Leonie Marie; Mall, Marcus A.; Stahl, Mirjam
title: Impact of lockdown during the COVID-19 pandemic on health status in patients with cystic fibrosis- a mono-center observational study
date: 2022-02-03
journal: ERJ Open Res
DOI: 10.1183/23120541.00588-2021
sha: 5a54f779165d6894ad363399017b2f9e01149dcf
doc_id: 989816
cord_uid: klnkw3tn

Patients with cystic fibrosis (CF) suffer from impaired mucociliary clearance making them more susceptible to a spectrum of inhaled pathogens including bacteria, fungi and viruses [1, 2]. Therefore, patients with CF were considered at high risk for serious illness following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection leading to “shielding or cocooning policies” [3]. Usually, patients with CF are cared for in specialised CF clinics with regular check-up visits. It was shown that regular care by multidisciplinary CF teams with highly trained staff lead to improvement in clinical outcomes in patient with CF [4]. At our centre, patients are usually seen at least quarterly. Between March and May 2020, at the peak of the first wave of SARS-CoV-2 infection in Germany, national authorities imposed an 8-week lockdown period on the entire population. During this period, hospitals and health care facilities reduced elective health care services including outpatient clinics to a minimum to focus their resources on the care of patients with coronavirus disease 2019 (COVID-19). Accordingly, all scheduled visits to our CF outpatient clinic were postponed and patients were advised to stay in home isolation. Additionally, due to lockdown measures, the patients’ possibilities for performing supportive therapies such as chest physiotherapy or physical exercise were limited. Hospital admission in case of severe clinical deterioration, e.g. pulmonary exacerbation, was available. Replacement of scheduled visits by e.g. video consultation or care by non-physician members of the multidisciplinary team was not yet implemented at this first lock-down period.

Patients with cystic fibrosis (CF) suffer from impaired mucociliary clearance making them more susceptible to a spectrum of inhaled pathogens including bacteria, fungi and viruses (1, 2) . Therefore, patients with CF were considered at high risk for serious illness following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection leading to "shielding or cocooning policies" (3) . Usually, patients with CF are cared for in specialized CF clinics with regular check-up visits. It was shown that regular care by multidisciplinary CF teams with highly trained staff lead to improvement in clinical outcomes in patient with CF (4). At our centre, patients are usually seen at least quarterly. Between March and May 2020, at the peak of the first wave of SARS-CoV-2 infection in Germany, national authorities imposed an 8-week lockdown period on the entire population. During this period, hospitals and health care facilities reduced elective health care services including outpatient clinics to a minimum to focus their resources on the care of patients with coronavirus disease 2019 (COVID-19). Accordingly, all scheduled visits to our CF outpatient clinic were postponed and patients were advised to stay in home isolation. Additionally, due to lockdown measures, the patients' possibilities for performing supportive therapies such as chest physiotherapy or physical exercise were limited. Hospital admission in case of severe clinical deterioration, e.g. pulmonary exacerbation, was available.

Replacement of scheduled visits by e.g. video consultation or care by non-physician members of the multidisciplinary team was not yet implemented at this first lock-down period.

The aim of this study was to assess the impact of home isolation during this lockdown period on the health status of patients with CF focusing on lung function outcomes. This mono-center observational study was performed at the CF center of the Charité-Universitätsmedizin Berlin caring for 269 patients with CF (median age 25.4; IQR 12.7-38.5; 93 patients (34.6%) <18 years of age). If receiving cystic fibrosis transmembrane conductance regulator (CFTR)-modulator therapy, patients had to receive this for more than three months before the start of the lockdown to be eligible for the study. Patients without lung transplantation or pulmonary exacerbation at time of spirometry, and at least one lung function test available within three months before and after the lockdown period were included. Spirometry was performed according to ATS/ERS criteria and percent predicted forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) was calculated according to global lung function initiative values (5, 6) . In case more than one lung function test was available in the 3-months period pre-or post-lockdown, the mean value of each To our knowledge, this is the largest study so far evaluating the effect of a lockdown period during the COVID-19 pandemic on lung function outcomes in pediatric and adult patients with CF. While lung function remained stable in the entire study population, there was a significant decline in FEV1 % predicted by 3.0 percentage points in our pediatric patients (Fig.1a) . Of note, patients of the Psa negative group, mainly younger than 18 years, experienced a significant decline of 4.2 percentage points of FEV1 % predicted. This decline in FEV1 % predicted exceeds the annual decline reported in registry studies (-0.5 to -2.6 percentage points) and CFTR modulator trials (-0.1 to -2.2 percentage points) (7-9) and was not observed in our study population in the year prior to the pandemic. In contrast, in patients chronically infected with Psa, lung function declined in the year prior to the lockdown, but remained stable with a trend towards improvement over the lockdown period (Fig. 1 c,d).

It is well established that CF care and patient outcomes improve if patients are seen regularly by trained, multidisciplinary CF teams. In a center-based analysis, more frequent monitoring and increased use of appropriate therapies were associated with an improved outcome in CF (4) . In addition to limited access to specialized CF care, supportive therapies like physiotherapy and sport opportunities were also markedly reduced during the lockdown period. A study in 327 patients with CF from Switzerland showed that lockdown measures led to substantially decreased levels of physical activity (10) . Physical exercise is routinely recommended in CF care because of its beneficial effect on general fitness, airway clearance, lung function and quality of life. Physical activity is associated with increased peak oxygen uptake (VO2peak), which in turn is linked to better survival in CF (11) . On the other hand, due to the implemented infection control measures, spreading of seasonal viral or bacterial infection was reduced substantially in the general population during lockdown periods. Accordingly, the number of visits to pediatricians in general practice and hospital admissions due to acute respiratory tract infection markedly declined during the lockdown period compared to previous years (12) . Preceding viral infections are an acknowledged risk factor for pulmonary exacerbations in CF (13) . With reduced exposure to respiratory pathogens, the number of pulmonary exacerbations decreased during the time of COVID-19 restrictions in patients with CF and non-CF bronchiectasis (14, 15) . Despite all this, FEV1 % predicted dropped significantly in patients without chronic Psa infection, including most of the pediatric patients, in our cohort, suggesting even short lockdown periods may have adverse effects on long-term outcomes of patients with CF. Especially reduced physical activity due to home isolation with limited access to sporting activities during lockdown might play a role in the younger age group.

The majority of chronically Psa-infected patients were adults, who might have been able to dedicate more time to CF therapy during the lockdown because of home office, reduced travel time and restricted social activities. Accordingly, lung function declined in Psa-infected patients in the pre-pandemic period, but was stable over the lockdown period. There was no difference in BMI (or BMI-percentile) pre-and postlockdown.

Our study is limited by its retrospective nature and the single center analysis.

Taken together, in the entire study group of patients with CF lung function remained stable over the first lockdown period in Germany. But our data indicate potential adverse effects of the first lockdown period with restricted access to healthcare and sporting activities on the subgroups of pediatric and not Psa-infected patients with CF. These findings may be aggravated by prolonged lockdown periods. Therefore, information on consequences of repetitive shutdowns and reduced availability of outpatient care over prolonged periods in patients with CF is urgently needed. This may also be relevant for other patient groups with chronic lung diseases depending on regular specialized care. 

Cystic fibrosis

CFTR: cystic fibrosis and beyond

COVID-19 meets Cystic Fibrosis: for better or worse?

Factors influencing outcomes in cystic fibrosis: a center-based analysis

Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations

Standardization of Spirometry

Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an openlabel extension study

Lung function over the life course of paediatric and adult patients with cystic fibrosis from a large multi-centre registry

Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study

Recommended shielding against COVID-19 impacts physical activity levels in adults with cystic fibrosis

The prognostic value of exercise testing in patients with cystic fibrosis

Effects of the SARS-CoV2-Lockdown on Pediatric Care in the Rhine-Main Area

Viral infections trigger exacerbations of cystic fibrosis in adults and children

Reduction of pulmonary exacerbations in young children with cystic fibrosis during the COVID-19 pandemic

The Impact of the COVID-19 Pandemic on Exacerbations and Symptoms in Bronchiectasis: A Prospective Study

Disclosures can be found alongside this article at erj.ersjournals.com